P
Phillip Monk
Researcher at Southampton General Hospital
Publications - 28
Citations - 1933
Phillip Monk is an academic researcher from Southampton General Hospital. The author has contributed to research in topics: Sputum & Asthma. The author has an hindex of 12, co-authored 25 publications receiving 1621 citations.
Papers
More filters
Journal ArticleDOI
Defective epithelial barrier function in asthma.
Chang Xiao,Sarah M. Puddicombe,Sarah A. Field,Joel Haywood,Victoria Broughton-Head,Ilaria Puxeddu,Hans Michael Haitchi,Elizabeth Vernon-Wilson,David Sammut,Nicole Bedke,Catherine Cremin,Jody Sones,Ratko Djukanovic,Peter H. Howarth,Jane E. Collins,Stephen T. Holgate,Phillip Monk,Donna E. Davies +17 more
TL;DR: The results show that the bronchial epithelial barrier in asthma is compromised, which may facilitate the passage of allergens and other agents into the airway tissue, leading to immune activation and may thus contribute to the end organ expression of asthma.
Journal ArticleDOI
Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial.
Phillip Monk,Richard J Marsden,Victoria Tear,Jody Brookes,Toby N Batten,Marcin Mankowski,Felicity J Gabbay,Donna E. Davies,Stephen T. Holgate,Stephen T. Holgate,Ling-Pei Ho,Tristan W Clark,Ratko Djukanovic,Tom Wilkinson,Michael G. Crooks,Davinder Dosanjh,Salman Siddiqui,Najib M. Rahman,Jacklyn A Smith,Alex Horsley,Tim Harrison,Dinesh Saralaya,Lorcan McGarvey,Alastair Watson,Edmund Foster,Adam Fleet,Dave Singh,Sophie Hemmings,Sandra Aitken,Sarah Dudley,Rona Beegan,Angela Thompson,Pedro Mb Rodrigues +32 more
TL;DR: Patients who received SNG001 had greater odds of improvement and recovered more rapidly from SARS-CoV-2 infection than patients who received placebo, providing a strong rationale for further trials.
Journal ArticleDOI
Increased sputum and bronchial biopsy IL-13 expression in severe asthma
S. Saha,Mike A. Berry,Deborah Parker,Salman Siddiqui,Angela Morgan,Richard D. May,Phillip Monk,Peter Bradding,Andrew J. Wardlaw,Ian D. Pavord,Christopher E. Brightling +10 more
TL;DR: IL-13 overexpression in sputum and bronchial biopsy specimens is a feature of severe asthma.
Journal ArticleDOI
The effect of inhaled IFN-β on worsening of asthma symptoms caused by viral infections. A randomized trial.
Ratko Djukanovic,Tim Harrison,Sebastian L. Johnston,Flic Gabbay,Peter A. B. Wark,Neil C. Thomson,Robert Niven,Dave Singh,Helen K. Reddel,Donna E. Davies,Richard J Marsden,Christine B. Boxall,Sarah Dudley,Vincent Plagnol,Stephen T. Holgate,Phillip Monk +15 more
TL;DR: It is suggested that inhaled IFN-β is a potential treatment for virus-induced deteriorations of asthma in difficult-to-treat people with asthma and supports the need for further, adequately powered, trials in this population.
Journal ArticleDOI
Sputum and bronchial submucosal IL-13 expression in asthma and eosinophilic bronchitis
Mike A. Berry,Deborah Parker,N Neale,Lucy Woodman,Angela Morgan,Phillip Monk,Peter Bradding,Andrew J. Wardlaw,Ian D. Pavord,Christopher E. Brightling +9 more
TL;DR: In this article, the authors investigated whether IL-13 expression is increased in asthma compared with eosinophilic bronchitis, and they found that the median number of cells expressing IL13 + cells/mm 2 submucosa was significantly higher in patients with mild asthma than in normal controls.